{
    "Symbol": "ARGX",
    "AssetType": "Common Stock",
    "Name": "argenx NV ADR",
    "Description": "argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.",
    "CIK": "1697862",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
    "Address": "INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-06-30",
    "MarketCapitalization": "29997107000",
    "EBITDA": "-242508000",
    "PERatio": "None",
    "PEGRatio": "0",
    "BookValue": "71.28",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-3.51",
    "RevenuePerShareTTM": "1.125",
    "ProfitMargin": "-0.123",
    "OperatingMarginTTM": "-0.0898",
    "ReturnOnAssetsTTM": "-0.0551",
    "ReturnOnEquityTTM": "-0.0574",
    "RevenueTTM": "1659620000",
    "GrossProfitTTM": "-251786000",
    "DilutedEPSTTM": "-3.51",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0.742",
    "AnalystTargetPrice": "537.77",
    "AnalystRatingStrongBuy": "8",
    "AnalystRatingBuy": "10",
    "AnalystRatingHold": "5",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "17.72",
    "PriceToBookRatio": "5.47",
    "EVToRevenue": "15.71",
    "EVToEBITDA": "-100.18",
    "Beta": "0.295",
    "52WeekHigh": "532.6",
    "52WeekLow": "327.73",
    "50DayMovingAverage": "425.6",
    "200DayMovingAverage": "414.84",
    "SharesOutstanding": "59796000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}